Market Scope (@MarketScope_LLC) header
Market Scope (@MarketScope_LLC) profile picture

Market Scope

@MarketScope_LLC
 St Louis, MO
market-scope.com
Joined December 2014
  • Tweets4.3K
  • Following620
  • Followers554
104Media
Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)Photo by Market Scope (@MarketScope_LLC)
Global Summit for Eye Health Draws Over $1 Billion in Commitments to Fight Avoidable Blindness: bit.ly/4zEkgMm

Global Summit for Eye Health Draws Over $1 Billion in Commitments to Fight Avoidable Blindness |...

World leaders, international agencies, and private sector partners met in St. John’s, the capital of Antigua and Barbuda, on Nov. 2 at the Global Summit for Eye Health, an event organized by the...

market-scope.com
7
US FDA Approves Ranibizumab (Lucentis) Biosimilar from Xbrane: bit.ly/3UNDFv4

US FDA Approves Ranibizumab (Lucentis) Biosimilar from Xbrane | Market Scope

Sweden’s Xbrane Biopharma announced Oct. 27 that the US FDA had approved its ranibizumab (Lucentis) biosimilar, to be branded Lucamzi in the US. It was approved to treat wet age-related macular...

market-scope.com
13
Lenz Announces Plans for Major Layoffs, CEO Switch: bit.ly/4z64DvR

Lenz Announces Plans for Major Layoffs, CEO Switch | Market Scope

Lenz Therapeutics, of San Diego, California, announced Oct. 28 a strategic reorganization to reduce projected 2027 annual operating expenses by over 50 percent as it continues to roll out Vizz, its...

market-scope.com
13
Harrow Launches HarrowRx Platform, Accessible to Doctors Through EMRs: bit.ly/4fmBNAm

Harrow Launches HarrowRx Platform, Accessible to Doctors Through EMRs | Market Scope

Nashville, Tennessee-based Harrow reported Nov. 2 that it had launched HarrowRx, allowing eye care providers to prescribe all of Harrow’s branded products within their electronic medical record (EMR)...

market-scope.com
14
Q3-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Tarsus, RxSight, and Xbrane: bit.ly/4AfYVZq

Q3-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Tarsus, RxSight, and Xbrane | Market...

Regeneron of Tarrytown, New York, reported Oct. 30 that its Q3-2026 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was just under $1.1 billion, a 1...

market-scope.com
7
EMA Grants Orphan Drug Status to BlueRock’s IRD Cell Therapy Candidate: bit.ly/47QcGSD

EMA Grants Orphan Drug Status to BlueRock’s IRD Cell Therapy Candidate | Market Scope

Bayer subsidiary BlueRock Therapeutics announced Sept. 30 that its investigational cell therapy, lemiretprocel (OpCT-001), had received orphan drug designation from the European Medicines Agency. The...

market-scope.com
16
Stuart Submits IND Amendment to US FDA for Trial of ST-100 in Corneal Wound Healing: bit.ly/4jNHFG2

Stuart Submits IND Amendment to US FDA for Trial of ST-100 in Corneal Wound Healing | Market Scope

Stuart Therapeutics announced Oct. 9 that it had submitted an investigational new drug application (IND) amendment to the US FDA to study its lead candidate, ST-100 (vezocolmitide) eye drops, in...

market-scope.com
10
RadiusXR, Topcon Introduce InspirePro Wearable Perimeter: bit.ly/4igMF4S
13
Visara Gains Exclusive Option to Acquire Candidate for Ocular Surface Squamous Neoplasia: bit.ly/4BzF3lH

Visara Gains Exclusive Option to Acquire Candidate for Ocular Surface Squamous Neoplasia | Market...

Visara, the ophthalmology subsidiary of NovaBridge Biosciences, announced Oct. 20 that it had gained an exclusive option to acquire worldwide rights to YOLO Immune’s YOL104-2, a candidate for ocular...

market-scope.com
14
Volk Launches ClearField Pro Lens for Retinal Exams, Laser Treatment: bit.ly/4kvgjVj

Volk Launches ClearField Pro Lens for Retinal Exams, Laser Treatment | Market Scope

Volk Optical announced Oct. 7 the launch of ClearField Pro, a new ophthalmic lens designed for retinal examination and laser indirect ophthalmoscopy. The lens’ advanced coating provides up to 77...

market-scope.com
9
Researchers Develop New Standardized Grading System for MGD: bit.ly/4zrHDsm

Researchers Develop New Standardized Grading System for MGD | Market Scope

A study published Oct. 6 in Clinical Optometry introduces the Meibomian Gland Composite Score (MGCS)—a standardized grading system that could help clinicians more precisely track meibomian gland...

market-scope.com
9
US FDA Gives Green Light to Trial of Opus’ Gene Therapy for RDH12-LCA: bit.ly/4BwrK5g

US FDA Gives Green Light to Trial of Opus’ Gene Therapy for RDH12-LCA | Market Scope

Opus Genetics announced on Oct. 21 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of OPGx-RDH12, a gene therapy...

market-scope.com
11
Q3-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, Novartis, Lumibird, and Lenz: bit.ly/4ikGJYx

Q3-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, Novartis, Lumibird, and Lenz |...

Bausch + Lomb reported Oct. 28 that its Q3-2026 revenue totaled $1.4 billion, a 7 percent increase (+8 percent cc) from $1.3 billion in Q3-2025. Ophthalmic pharmaceuticals segment revenue was $367...

market-scope.com
1
31
Appasamy Acquires Ruck and its Qube Pro Dual-Function Platform: bit.ly/48q6RLM

Appasamy Acquires Ruck and its Qube Pro Dual-Function Platform | Market Scope

India’s Appasamy Associates, a portfolio company of Warburg Pincus, reported Oct. 22 that it had acquired German company Ruck, manufacturer of ophthalmic surgical products for both the front and back...

market-scope.com
17
US FDA Advisory Panel Meets to Review Sydnexis’ Rejected Myopia Drop, Hear Public Comments: bit.ly/4zr2BHU

US FDA Advisory Panel Meets to Review Sydnexis’ Rejected Myopia Drop, Hear Public Comments | Market...

The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee held a meeting and open public hearing on Oct. 30 in Silver Spring, Maryland, to review the new drug application (NDA) for Sydnexis’...

market-scope.com
15
Haag-Streit and Marco Lombart Launch Octopus 910 Perimeter in the US: bit.ly/4AfXE4P

Haag-Streit and Marco Lombart Launch Octopus 910 Perimeter in the US | Market Scope

Haag-Streit USA and distributor Marco Lombart reported Oct. 10 that they had launched the Octopus 910 perimeter in the US. A global launch is set for January 2027. The full-field projection perimeter...

market-scope.com
9
Belite Files for Approval of Oral Stargardt Candidate in Singapore, UK, Switzerland: bit.ly/4yHCo6E

Belite Files for Approval of Oral Stargardt Candidate in Singapore, UK, Switzerland | Market Scope

Belite Bio announced Oct. 14 that it had filed for marketing approval for its oral Stargardt treatment candidate, tinlarebant, in three countries—Singapore, the UK, and Switzerland—under those...

market-scope.com
12
EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu: bit.ly/4jHsWMQ

EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu | Market Scope

EyePoint announced Oct. 19 that it would cut its workforce by 53 percent and end the Phase III trials for Duravyu in wet age-related macular degeneration (AMD) early after the LUCIA study failed to...

market-scope.com
12
US FDA Approves Ryzumvi from Opus and Viatris for Presbyopia: bit.ly/4zdiyRZ

US FDA Approves Ryzumvi from Opus and Viatris for Presbyopia | Market Scope

Commercial partners Viatris and Opus Genetics reported Oct. 16 that the US FDA had approved Ryzumvi (phentolamine ophthalmic solution 0.75%) as a treatment for presbyopia. The milestone marks the...

market-scope.com
15
US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops: bit.ly/4ifhtS7

US FDA Approves Alcon’s Brytly 12-Hour Redness Reliever Eye Drops | Market Scope

Alcon announced Oct. 16 that the US FDA had approved Brytly (apraclonidine 0.125%), a redness relieving eye drop. The company said one drop of Brytly works in one minute and lasts up to 12 hours,...

market-scope.com
10
Load more